Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.

Date publication

mars 2025

Journal

Cancer epidemiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr LORGIS Véronique

Tous les auteurs :
Passildas J, Paillard MJ, Uwer L, Molnar I, Dohollou N, Petit T, Hajjaji N, Boudin L, Lorgis V, Jacquin JP, Abrial C, Mouret-Reynier MA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40090228

Résumé

Eribulin can represent a therapeutic alternative for patients with advanced breast cancer who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy. In this observational study, we focused on long-responder patients, i.e. with an objective response or stability ≥ 6 months under eribulin to better characterize them.

Mots clés

Eribulin, Hepatic disease, Long-responder, Metastatic breast cancer, Observational study, Second-line treatment

Référence

Cancer Epidemiol. 2025 03 15;96:102800